India Regulator Caps Prices Of Ranbaxy ED Drug, Antibiotic
This article was originally published in PharmAsia News
Executive Summary
India's drug price regulator has imposed a cap on the cost of generics of an erectile dysfunction drug and an antibiotic, both made by Ranbaxy Laboratories. The National Pharmaceutical Pricing Authority capped the price of Caverta, Ranbaxy's version of Pfizer's Viagra (sildenafil citrate) and its Cilanem antibiotic injection version of Merck's Primaxin (cilastatin sodium, imipenem). Ranbaxy has asked for a review of the NPPA ruling at the ministerial level, arguing the agency is inconsistent in its pricing decisions for similar drugs. (Click here for more